Sch 34343

06/01/1985 - "On the basis of these promising results, Sch 34343 merits further in-vitro and in-vivo study to define its potential usefulness in treatment of infections with these pathogens in humans."
06/01/1985 - "We concluded that Sch 34343 is a highly promising agent with a broad spectrum of activity making it potentially suitable as monotherapy for patients with infection of undetermined bacterial aetiology, particularly if Bact. "
06/01/1985 - "Sch 34343 is a promising agent for the treatment of anaerobic infections because it can penetrate into anaerobic abscesses and can kill large numbers of bacteria within abscesses."
06/01/1985 - "On the basis of its activity in vitro, Sch 34343 appears to be one of the most promising new antimicrobial agents for the treatment of infections involving anaerobic bacteria."
06/01/1985 - "Based on these results, Sch 34343 appears to be a promising antimicrobial agent for anaerobic infections and warrants further clinical investigations."

08/01/1986 - "In-vitro activity of Sch 34343, a new penam, against gram-positive isolates from cancer patients."
01/01/1986 - "In vitro activity of SCH-34343, a new penam, and other antimicrobial agents against clinical isolates from cancer patients."
01/01/1986 - "The in vitro activity of SCH-34343, a new penam antibiotic, was tested against gram-positive and gram-negative isolates from cancer patients, and compared to that of 7 other antimicrobial agents. "
08/01/1986 - "The in-vitro activity of Sch 34343, a new penam antibiotic, was tested against 257 Gram-positive isolates from cancer patients, and compared with that of imipenem and amifloxacin. "

06/01/1985 - "Within 1 h after injection of Sch 34343, the drug was present in higher concentrations in the abscesses than in the blood of infected animals. "
06/01/1985 - "In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses."
06/01/1985 - "After five days of Sch 34343 therapy with either 100 or 400 mg/kg administered five times a day to mice with subcutaneous abscesses, the numbers of Bact. "
06/01/1985 - "Sch 34343 is a promising agent for the treatment of anaerobic infections because it can penetrate into anaerobic abscesses and can kill large numbers of bacteria within abscesses."
06/01/1985 - "In an anaerobic abscess model in mice, Sch 34343 was more active than cefoxitin and clindamycin against Bacteroides fragilis. "

06/01/1985 - "Pharmacokinetic parameters of Sch 34343 have been determined for mice, rats, rabbits, monkeys, dogs and humans and correlated among species as an exponential function of body weight. "